Drugs / LAIV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07545564 | Apr 2026 overdue | influenza | Changchun BCHT Biotechnology Co. | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LAIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07545564 ↗ |
| Modality | Vaccine | “Nasal spray live attenuated influenza vaccine” NCT07545564 ↗ |
| Route | Intranasal | “Nasal spray live attenuated influenza vaccine” NCT07545564 ↗ |